CPIX
Cumberland Pharmaceuticals Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.79
+0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 31.3M | 44.5M | 37.9M | 39.6M | 42.0M |
| Cost of Revenue | 5.2M | 6.7M | 6.6M | 6.1M | 9.1M |
| Gross Profit | 26.1M | 37.9M | 31.3M | 33.5M | 32.9M |
| Operating Expenses | |||||
| R&D Expense | 5.0M | 5.6M | 4.8M | 5.8M | 6.7M |
| SG&A Expense | 27.4M | 31.0M | 28.1M | 29.1M | 26.8M |
| General & Admin Expense | 11.7M | 11.9M | 11.1M | 10.7M | 10.2M |
| Selling & Marketing Expense | 15.7M | 19.1M | 17.0M | 18.5M | 16.7M |
| Other Expenses | 3.2M | 4.0M | 4.7M | 8.1M | 5.1M |
| Total Operating Expenses | 35.7M | 40.6M | 37.7M | 43.0M | 38.6M |
| Cost and Expenses | 40.9M | 47.3M | 44.3M | 49.1M | 47.7M |
| Operating Income (EBIT) | (9.6M) | (2.8M) | (6.4M) | (9.6M) | (5.7M) |
| Non-Operating | |||||
| Interest Income | 362.5K | 476.7K | 334.4K | 286.9K | 98.4K |
| Interest Expense | 309.2K | 496.0K | 605.5K | 667.9K | 586.0K |
| Net Interest Income | 53.3K | (19.2K) | (271.1K) | (381.0K) | (487.6K) |
| Other Non-Op Income/Expense | 40.0K | (32.5K) | (34.0K) | 3.3M | 123.7K |
| Non-Operating Income (excl Interest) | (301.6K) | (463.5K) | (571.5K) | (3.9M) | (709.7K) |
| EBT (Pre-Tax Income) | (9.6M) | (2.8M) | (6.5M) | (6.3M) | (5.6M) |
| Income Tax Expense | 36.7K | 40.3K | (22.7K) | 45.8K | 68.8K |
| Bottom Line | |||||
| Net Income | (10.6M) | (2.8M) | (6.5M) | (6.3M) | (5.6M) |
| Earnings from Cont. Ops | (9.6M) | (2.9M) | (6.4M) | (6.3M) | (5.7M) |
| Earnings from Discont. Ops | (1.0M) | — | — | — | — |
| Bottom Line Net Income | (10.8M) | (2.8M) | (6.5M) | (6.3M) | (5.6M) |
| Per Share | |||||
| Basic EPS | ($0.71) | ($0.19) | ($0.46) | ($0.44) | ($0.38) |
| Diluted EPS | ($0.71) | ($0.19) | ($0.46) | ($0.44) | ($0.38) |
| Revenue Per Share | $2.09 | $2.98 | $2.69 | $2.77 | $2.88 |
| Shares | |||||
| Basic Shares Outstanding | 15.0M | 15.0M | 14.1M | 14.3M | 14.6M |
| Diluted Shares Outstanding | 15.0M | 15.0M | 14.1M | 14.3M | 14.6M |
| Profitability Metrics | |||||
| EBITDA | (5.6M) | 3.0M | 182.4K | 2.5M | 332.9K |
| D&A | 3.7M | 5.3M | 6.0M | 8.1M | 5.3M |
| EBIT | (9.3M) | (2.3M) | (5.9M) | (5.6M) | (5.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026